After so many announcements of new facility builds in the US, Eli Lilly has made a welcome commitment to a European investment.
Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffra
Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug. In an interview with Endpoints News


